Gestalt Diagnostics

About Gestalt Diagnostics

Gestalt Diagnostics, a Spokane-based company, is positioned to address the evolving needs of the pathology sector, a field facing pressures from rising cancer rates and a declining number of specialists. The company was established in 2017, originating as a spin-off from Inland Imaging, a radiology firm with a long history of digitization. Leaders at Inland Imaging recognized the potential to apply their experience in digital radiology workflows to the pathology space, leading to the creation of Gestalt. The company was co-founded by Dan Roark, a serial entrepreneur and angel investor, and Jon Copeland in 2015 as a joint venture before its formal launch.

The core of Gestalt's offering is PathFlow®, a cloud-based, enterprise software platform designed to transition anatomic pathology laboratories from manual, microscope-based processes to an integrated digital workflow. This vendor-neutral platform serves as a central hub for pathologists, allowing them to manage images from various scanners, utilize AI-powered analysis tools, and collaborate with colleagues in real-time, regardless of location. The business model centers on providing this software as a service to clients that include healthcare organizations, academic medical centers, research institutions, and pathology groups. Revenue is generated by replacing traditional microscopes and paper-based systems with its digital solution, aiming to enhance efficiency and diagnostic accuracy. The platform is designed to integrate with existing Laboratory Information Systems (LIS) and hospital records, creating a unified cockpit for pathologists.

PathFlow is a modular system, offering professional, educational, and research components that clients can adapt to their specific needs. The professional module focuses on streamlining clinical case review, while the education module provides tools for training, proficiency testing, and credentialing. The research module supports preclinical and clinical trials by managing large libraries of digital images for analysis. A key feature is its interoperability, enabling the integration of third-party AI algorithms for tasks like biomarker scoring and cell quantification, which helps in matching patients to therapies and supports drug development research. This capability was highlighted when BioReference Laboratories, a major U.S. lab, adopted PathFlow integrated with an AI algorithm to detect and quantify breast cancer cells.

Since its inception, Gestalt has expanded through strategic acquisitions, including Peak Medical in 2018 to bolster its integration and IT support services. The company has steadily secured funding to fuel its growth, raising over $14 million across several rounds. A significant Series A round in April 2025 brought in $7.5 million, led by investors such as Cowles Ventures, TVF Funds, and Inland Imaging Investments, with the stated goals of expanding its customer base, enhancing AI capabilities, and pursuing FDA clearance to facilitate broader market adoption.